¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"family group"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • symmetry group
    ´ëαº
  • taxonomic group
    ºÐ·ùÁý´Ü
  • topological group
    À§»ó±º
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªºÐ¼®(¹ý)
  • Rh blood group system
    ¾Ë¿¡ÃëÇ÷¾×Çü±º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • haptenic group
    ÇÕÅÙ±â(¡­Ðñ).
  • hearing aid, group
    Áý´Üº¸Ã»±â
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(¡­Ðñ).
  • incompatibility group, plasmid
    ÇÃ¶ó½º¹Ìµå ºñÀûÇÕ±º
  • indeterminate group
    ¹ÌÁ¤Çü±º(Ú±ïÒúþÏØ).
  • indeterminate group
    ¹ÌÁ¤Çü±º(ËÑËøÌ´Ë´).
  • posterior group of aphasia
    ÈĺνǾ(ý­Ý»ã÷åÞÏØ).
  • posterior group of aphasia
    ÈĺνǾ(ý­Ý»ã÷åÞÏØ)
  • prepaid group practice
    ¼±ºÒÁ¦Áý´Ü°³¿ø.
  • prostheitc group
    ¹èÇÕ±º(ÛÕùêÏØ).
  • prosthetic group-labeled enzyme
    º¸Á¶±ºÇ¥ÁöÈ¿¼Ò
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªÃøÁ¤(¹ý)
  • psittacosis-lymphogranuloma-trachoma (PLT) group
    PLT±º Ŭ¶ó¹Ìµð¾Æ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • group I fiber
    Á¦¥°¤Çí·A(ð¯ìéÏØàéë«).
  • group II fiber
    Á¦¥± ±º¼¶À¯(ÏØàéë«).
  • group II fiber
    Á¦¥±¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • group IV fiber
    Á¦¥³±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
  • group discussion
    Áý´ÜÅäÀÇ(̤ËÀ̬Ëö).
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢(ÊÙËÒ ËôËÑ̬).
  • group dynamics
    Áý´Ü¿ªÇÐ(ÊÙËç ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • methylene group
    ¸ÞÆ¿·»±â(Ðñ)
  • methyl group
    ¸ÞÆ¿±â(Ðñ)
  • MN blood group system
    MN½Ä(ãÒ)Ç÷¾×Çü(úìäûúþ)
  • neighboring group effect
    ±ÙÁ¢±â È¿°ú(ÐÎïÈÐïüùÍý)
  • neuraminosyl group
    ´º¶ó¹Ì³ë½Ç±â(Ðñ)
  • neuroaminoyl group
    ´º·Î¾Æ¹Ì³ëÀϱâ(Ðñ)
  • nitroso group
    ³ªÀÌÆ®·Î¼Ò±â(Ðñ)
  • P blood group
    P Ç÷¾×±º(úìäûÏØ)
  • phenolic group
    Æä³î±â(Ðñ)
  • phenolic hydroxyl group
    Æä³î ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • phosphate group
    Àλê±â(×òß«Ðñ)
  • phosphate group transfer
    Àλê±â ÀüÀÌ(×òß«Ðñï®ì¹)
  • phosphatidal group
    Æ÷½ºÆÄƼ´Þ±â(Ðñ)
  • phosphatidyl group
    Æ÷½ºÆÄƼµô±â(Ðñ)
  • phosphoryl group
    ÀλêÈ­±â(×òß«ûùÐñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
FAT family attitudes test; fluorescent antibody technique; fluorescent antibody test
FCH faculty contact hour; family case home; fetal cystic hygroma
FCMC familial chronic mucocutaneous candidiasis; family centered maternity care
FD familial dysautonomia; family doctor; fan douche; fatal dose; fetal danger; fibrin derivative; fibro...
FDDS Family Drawing Depression Scale
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
FHSA Family Health Service Authority
FH Family History
FHN Family History Negative
FHP Family History Positive
FH-RDC Family History Research Diagnostic Criteria
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
group agglutination Agglutination by antibodies specific for minor (group) antigens common to several microorganisms, each of which possesses its own major specific antigen.
Synonym: cross agglutination.
(05 Mar 2000)
group agglutinin An immune agglutinin specific for a group antigen.
Synonym: cross-reacting agglutinin.
(05 Mar 2000)
group antigens Antigen's that are shared by related genera of microorganisms.
(05 Mar 2000)
group A streptococcal necrotizing fasciitis A complication of infection with GAS (group A streptococci) in which the bacteria attacks and destroys muscle tissue. According to the CDC, 5-10% of people with severe GAS infection develop necrotizing fasciitis. Though the infection can be treated with antibiotics, the fatality rate is close to 30%. This complication often develops as a wound infection after surgery or injury.
(05 Mar 2000)
group A streptococci A common bacteria that is the cause of strep throat, scarlet fever, impetigo, cellulitis-erysipelas, rheumatic fever, acute glomerular nephritis, endocarditis, and group A streptococcal necrotizing fasciitis. The prototype is Streptococcus pyogenes.
(05 Mar 2000)
group B streptococci A leading cause of a form of neonatal sepsis that has a 10-20% mortality rate and leaves a large number of survivors with brain damage. Also a leading cause of meningitis.
(05 Mar 2000)
group dynamics A term used to represent the study of underlying features of group behaviour, e.g., motives, attitudes; it is concerned with group change rather than with static characteristics.
(05 Mar 2000)
group homes Housing for groups of patients, children, or others who need or desire emotional or physical support. They are usually established as planned, single housekeeping units in residential dwellings that provide care and supervision for small groups of residents, who, although unrelated, live together as a family.
(12 Dec 1998)
group hospital A private hospital organised and controlled by a group of physicians and restricted to the reception and care of their own patients.
(05 Mar 2000)
group III mycobacteria Mycobacteria that are either colourless or that slowly produce a light yellow pigment when grown in the presence of light. Organisms placed in this group belong to the species Mycobacterium intracellulare.
Synonym: nonchromogens.
(05 Mar 2000)
group II mycobacteria Mycobacteria that produce a yellow pigment even when grown in the dark; when grown in the light, the pigment is orange. These organisms behave as do saprophytes in humans and are nonpathogenic to laboratory animals.
Synonym: scotochromogens.
(05 Mar 2000)
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
group I mycobacteria Mycobacteria that produce a bright yellow colour when grown in the presence of light. Organisms placed in this group appear to belong to the species Mycobacterium kansasii.
Synonym: photochromogens.
(05 Mar 2000)
group IV mycobacteria Mycobacteria that grow rapidly and that do not produce pigment. Organisms placed in this group belong to such species as Mycobacterium ulcerans and M. Marinum.
(05 Mar 2000)
group practice Any group of three or more full-time physicians organised in a legally recognised entity for the provision of health care services, sharing space, equipment, personnel and records for both patient care and business management, and who have a predetermined arrangement for the distribution of income.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • group theory
    ±º·Ð
  • group therapy
    Áý´Ü ¿ä¹ý
  • group velocity
    (ÆÄµ¿ÀÇ)±º¼Óµµ
  • group work
    Áý´Ü(»çȸ)»ç¾÷
  • habitat group
    »ýÅ·ù(¼­½Ä ȯ°æÀ» °°ÀÌ ÇÏ´Â µ¿½Ä¹°);(¹Ú¹°°ü¿¡ Àü½ÃµÈ)»ý¹° ȯ°æ ¸ðÇü
  • income group
    »çȸ ¼ÒµæÃþ(µ¿ÀÏ ¼Òµæ¼¼¾×Áý´Ü)
  • informal group
    (»çȸ)ºñ°ø½ÄÀû Áý´Ü(°üû°øÀåµî¿¡¼­ÀÇ)
  • interested group
    (»çȸ)ÀÌÀͰøµ¿Ã¼;°øÅëÀÌÇØ´Üü(±¹°¡ Á¤´çŬ·´µî)
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
  • rape group
    ÅäÀÇ(Åä·Ð)±×·ì
  • reference group
    ÁذŠÁý´Ü(°³ÀÎÀÌ ÀÚ±â ŵµ.ÆÇ´ÜÀÇ ±âÁØÀ¸·Î ¿©±â´Â ƯÁ¤ Áý´Ü)
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á